May 24, 2018 – The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down…Original Article
FDA Approves Palynziq (pegvaliase-pqpz) for the Treatment of Adults with Phenylketonuria
